Evidence map›Paper›PMID 36505943›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2022

Characteristics of antifungal utilization for hospitalized children in the United States.

Lourdes Eguiguren, Brian R Lee, Jason G Newland, Matthew P Kronman, Adam L Hersh, Jeffrey S Gerber, Grace M Lee, Hayden T Schwenk

Open access · goldAbstract read
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Lourdes EguigurenDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska.ORCID https://orcid.org/0000-0002-0851-4327
Brian R LeeDivision of Health Services and Outcomes Research, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri.
Jason G NewlandDivision of Infectious Diseases, Department of Pediatrics, Washington University in St Louis, St Louis, Missouri.
Matthew P KronmanDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington.ORCID https://orcid.org/0000-0002-1856-6841
Adam L HershDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah, Salt Lake City, Utah.ORCID https://orcid.org/0000-0002-0148-046X
Jeffrey S GerberDivision of Pediatric Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Grace M LeeDivision of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, California.
Hayden T SchwenkDivision of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-8164-8655
Stanford University · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USUniversity of Nebraska Medical Center · USUniversity of Utah · USUniversity of Washington · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To characterize antifungal prescribing patterns, including the indication for antifungal use, in hospitalized children across the United States. Design: We analyzed antifungal prescribing data from 32 hospitals that participated in the SHARPS Antibiotic Resistance, Prescribing, and Efficacy among Children (SHARPEC) study, a cross-sectional point-prevalence survey conducted between June 2016 and December 2017. Methods: Inpatients aged <18 years with an active systemic antifungal order were included in the analysis. We classified antifungal prescribing by indication (ie, prophylaxis, empiric, targeted), and we compared the proportion of patients in each category based on patient and antifungal characteristics. Results: Among 34,927 surveyed patients, 2,095 (6%) received at least 1 systemic antifungal and there were 2,207 antifungal prescriptions. Most patients had an underlying oncology or bone marrow transplant diagnosis (57%) or were premature (13%). The most prescribed antifungal was fluconazole (48%) and the most common indication for antifungal use was prophylaxis (64%). Of 2,095 patients receiving antifungals, 79 (4%) were prescribed >1 antifungal, most often as targeted therapy (48%). The antifungal prescribing rate ranged from 13.6 to 131.2 antifungals per 1,000 patients across hospitals ( Conclusions: Most antifungal use in hospitalized children was for prophylaxis, and the rate of antifungal prescribing varied significantly across hospitals. Potential targets for antifungal stewardship efforts include high-risk, high-utilization populations, such as oncology and bone marrow transplant patients, and specific patterns of utilization, including prophylactic and combination antifungal therapy.

Identifiers

PMID36505943
PMCPMC9726632
OpenAlexW4311289342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.